Abbott and Johnson & Johnson both put forward separate clinical studies for their platforms for coronary intravascular lithotripsy, or IVL, designed to break through hardened plaque in the arteries feeding the heart muscle. Both trials demonstrated low rates of complications after 30 days, and were largely able to cross through lesions for a … [Read more...] about Abbott, J&J spotlight clinical successes in coronary intravascular lithotripsy

